Scientist's Selfless Act Could Provide a Lead for Treating TNBC
Dr Koss refused preoperative chemotherapy to avoid damaging her virulent cells, which could later be cultured and could likely provide therapeutic leads.
The Gluttony of Cancer Cells
The authors observed that an artificial switch in cancer cells from an epithelial to a mesenchymal phenotype induced the expression of GLUT3, a protein that promotes cellular glucose uptake.
Bevacizumab and Cetuzimab: Equivalent OS in mCRC
Molecular analysis is now underway to characterize subsets of patients who performed better or worse on either treatment.
$1,000 Sovaldi Now Hepatitis Treatment of Choice
Even with insurers reluctant to pay, Sovaldi prescriptions have eclipsed those for all other hepatitis C pills combined in a matter of months, new data from IMS Health indicate. The promise of a real cure, with fewer nasty side effects, has prompted thousands to get treated.
In Medicare, Connecting Medical and Drug Coverage Results in Richer Benefits, AJMC Study Finds
A study just published in The American Journal of Managed Care examined how benefit design differences affected seniors who received prescription coverage through Medicare Advantage compared with a stand-alone Medicare drug plan. The review showed that integrating drug coverage with medical care resulted in fewer barriers to name-brand drugs, with lower copayments.
States That Deny Anti-Psychotics to the Poor Have Lots of Mentally Ill People Behind Bars
A team of researchers published data Tuesday in the American Journal of Managed Care showing that prior authorization policies in Medicaid programs have significantly higher rates of severe mental illness in their prison populations.
Gilead's Idelalisib Receives CHMP Recommendation for Treating CLL and FL
The recommendation to the EMA came soon after Zydiga (idelalisib) was approved in the US.
Vague Definitions of Health Plan and Payer Create Challenges
Common misuse of the terms health plan and payer is making it difficult for the payer community to comply with the Health Plan Identifier (HPID) final rule, according to the Workgroup for Electronic Data Interchange (WEDI).
Under Pressure to Run Insurance Exchanges, States Wary of Glitches
Given the vast technology problems many state-based exchanges experienced during the first open-enrollment period, state officials there and elsewhere remain wary of running their own websites.
First, Do No Harm: AJMC Commentary Calls for New Framework for Comparative Effectiveness Research
Not every patient responds the same way to the same treatment, yet healthcare is moving toward a system based on population health. How can researchers, health plans, and providers respond? This month in The American Journal of Managed Care, Jennifer S. Graff, PharmD, and co-authors call for an approach that identifies when differences in patient responses are mostly like to matter, and offering greater flexibility when the patient’s health is most at stake.
Clinical Trial Will Evaluate Drug's Ability to Protect Normal Cells During Chemotherapy
The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.
FDA Approves Imbruvica for Treating Chromosome 17-Deletion CLL Patients
New trial data confirms its use as standard therapy for CLL.
Study Reports Exclusion from Trials Responsible for Poor Outcomes in HIV-Positive Cancer Patients
HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.
Tentative Deal Reached on VA Reform
The chairmen of the House and Senate Veterans Affairs committees have reached a tentative agreement on a plan to improve veterans' healthcare.
23andMe Tries to Woo the FDA
The DNA testing firm hopes a more cooperative approach with regulators will get its business back on track.
AstraZeneca Investing in Blood Test to Personalize NSCLC Treatment
AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.
US Paves Way for Novartis to Copy Amgen Biotech Drug
U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.
Innovative Approaches by Pharmacists Save Costs at a Comprehensive Cancer Center
Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.
Without Medicaid,Hospitals May Pay Patient Premiums
Uncompensated care was supposed to be a thing of the past, but it's persisting in many states not expanding Medicaid eligibility. As an alternative, for some high-cost uninsured patients, hospitals are turning to a new option.
For Better Treatment, Doctors And Patients Share The Decisions
When weighing the risk of heart disease, how the numbers are presented to patients can make all the difference.
Care Coordination Pilot Looks to Prevent Hospital Readmissions
The University of Buffalo is working to limit patient readmissions to hospitals and ERs via use of dashboard technology.
BMS Announces Collaboration With Ono Pharmaceutical to Market Opdivo
Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.
CDC Lab Safety Point Person, Dr. Michael Bell, to Give Keynote on Hospital Safety at AJMCLive Event
Dr. Michael Bell, previously announced as the keynote speaker for the September 25-26 live meeting hosted by The American Journal of Managed Care, this weekend discussed his role in overhauling lab safety at the Centers for Disease Control and Prevention in Atlanta. Attendees at AJMCLive’s Atlanta conference, “Value-Based Decision-Making in Infectious Disease,” will have the chance to hear Dr. Bell discuss the prevention of hospital-acquired infections.
ACO, Health Insurance Exchange Pressures Mounting
As healthcare reform advances, experts say, dermatologists face mounting pressure to prove their mettle to insurance exchanges and accountable care organizations (ACOs).
Medical-Loss Ratio Prompted Insurers to Refund $332 Million Last Year
A federal rule requiring health insurers to spend a minimum percentage of premium dollars on medical care led to more than $332 million in rebates last year, according to HHS.